Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Gossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price drop. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.